Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLYS, SRRK, KLRS, SEPN, NGNE, and represent 78.56% of Samsara BioCapital's stock portfolio.
- Added to shares of these 4 stocks: MLYS (+$22M), AQST (+$14M), ABVX (+$6.4M), VTVT.
- Started 2 new stock positions in AQST, ABVX.
- Reduced shares in these 10 stocks: CRGX (-$18M), UPB (-$9.0M), PVLA (-$8.2M), AURA, RYTM, ZYME, ACLX, TNGX, Hillevax, TERN.
- Sold out of its positions in ARTV, CRGX, Hillevax, TNGX.
- Samsara BioCapital was a net buyer of stock by $144k.
- Samsara BioCapital has $766M in assets under management (AUM), dropping by 56.65%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 27 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics (MLYS) | 31.0 | $238M | +10% | 6.3M | 37.92 |
|
| Scholar Rock Hldg Corp (SRRK) | 27.3 | $209M | 5.6M | 37.24 |
|
|
| Kalaris Therapeutics (KLRS) | 8.6 | $66M | 11M | 5.78 |
|
|
| Septerna (SEPN) | 7.7 | $59M | 3.1M | 18.81 |
|
|
| Neurogene (NGNE) | 3.9 | $30M | 1.7M | 17.33 |
|
|
| Alumis (ALMS) | 2.5 | $19M | 4.8M | 3.99 |
|
|
| Upstream Bio (UPB) | 2.4 | $18M | -33% | 962k | 18.81 |
|
| Gossamer Bio (GOSS) | 2.1 | $16M | 6.1M | 2.63 |
|
|
| Lenz Therapeutics (LENZ) | 2.1 | $16M | 343k | 46.58 |
|
|
| Aquestive Therapeutics (AQST) | 1.8 | $14M | NEW | 2.5M | 5.59 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 1.7 | $13M | -38% | 210k | 62.69 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 1.3 | $10M | 676k | 15.27 |
|
|
| Vtv Therapeutics Cl A New (VTVT) | 1.1 | $8.7M | +81% | 375k | 23.35 |
|
| Nkarta (NKTX) | 1.0 | $7.8M | 3.8M | 2.07 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.9 | $6.7M | -3% | 571k | 11.75 |
|
| Arcellx Common Stock (ACLX) | 0.9 | $6.7M | -20% | 81k | 82.10 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.8 | $6.4M | NEW | 75k | 84.90 |
|
| Jade Biosciences Com New (JBIO) | 0.6 | $4.6M | 531k | 8.63 |
|
|
| Aura Biosciences (AURA) | 0.5 | $3.6M | -41% | 585k | 6.18 |
|
| Zymeworks Del (ZYME) | 0.5 | $3.6M | -33% | 208k | 17.08 |
|
| Surrozen Com New (SRZN) | 0.4 | $3.1M | 241k | 12.88 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.4 | $3.1M | -40% | 30k | 100.99 |
|
| Sutro Biopharma (STRO) | 0.2 | $1.9M | 2.2M | 0.87 |
|
|
| Terns Pharmaceuticals (TERN) | 0.1 | $1.0M | -33% | 136k | 7.51 |
|
| Bolt Biotherapeutics Com New (BOLT) | 0.0 | $260k | -6% | 49k | 5.32 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $27k | 133k | 0.20 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.8k | 100k | 0.02 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2025 Q3 filed Nov. 14, 2025
- Samsara BioCapital 2025 Q2 filed Aug. 14, 2025
- Samsara BioCapital 2025 Q1 filed May 15, 2025
- Samsara BioCapital 2024 Q4 filed Feb. 14, 2025
- Samsara BioCapital 2024 Q3 filed Nov. 14, 2024
- Samsara BioCapital 2024 Q2 filed Aug. 14, 2024
- Samsara BioCapital 2024 Q1 filed May 15, 2024
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023
- Samsara BioCapital 2022 Q4 filed Feb. 14, 2023
- Samsara BioCapital 2022 Q3 filed Nov. 14, 2022
- Samsara BioCapital 2022 Q2 filed Aug. 15, 2022